Why Market Size Forecasters?
- Reports at Lowest Prices - Guaranteed
- Fastest Growing Research Reports’ Database
- Easy Customization Options
- 24 X 7 Support Commitment
- Certified, Safe & Secured Payments
About Premature Ejaculation Treatment Premature ejaculation is one of the most common sexual dysfunctions occurring in men. Ejaculation happens sooner than desired, either shortly or before penetration, resulting in distress to either one or both partners involved in sexual intercourse. There is no exact cause that can be associated with the condition though mostly, premature ejaculation can be attributed to personal distress and anxiety. It can affect an individual's relationship with his partner. Premature ejaculation is the most common sexual disorder found in men aged between 18 to 59. Some of the effective treatment options available include psychological counseling, medications, sexual techniques that delay ejaculation, or a combination of these treatments. Technavio?s analysts forecast the global premature ejaculation treatment market to grow at a CAGR of 8.71% during the period 2017-2021. Covered in this report The report covers the present scenario and the growth prospects of the global premature ejaculation treatment market for 2017-2021. To calculate the market size, the report considers the sales of branded, generic, and off-label drugs. The market is divided into the following segments based on geography: ? Americas ? APAC ? EMEA Technavio's report, Global Premature Ejaculation Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. Key vendors ? Absorption Pharmaceuticals ? Bayer ? Eli Lilly ? Regent Pacific Group Other prominent vendors ? Dong-A Pharmaceutical ? Emcure ? Futura Medical ? GlaxoSmithKline ? NeuroHealing Pharmaceuticals ? Pfizer Market driver ? High use of off-label drugs ? For a full, detailed list, view our report Market challenge ? Alternative treatments ? For a full, detailed list, view our report Market trend ? Growing online retail sales of drugs ? For a full, detailed list, view our report Key questions answered in this report ? What will the market size be in 2021 and what will the growth rate be? ? What are the key market trends? ? What is driving this market? ? What are the challenges to market growth? ? Who are the key vendors in this market space? You can request one free hour of our analyst?s time when you purchase this market report. Details are provided within the report.
Table of Contents PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT PART 03: RESEARCH METHODOLOGY PART 04: INTRODUCTION ? Market outline PART 05: PREMATURE EJACULATION: DISEASE OVERVIEW PART 06: MARKET LANDSCAPE ? Market overview ? Five forces analysis PART 07: PIPELINE LANDSCAPE PART 08: MARKET SEGMENTATION BY ROUTE OF ADMINISTRATION ? Oral route of administration ? Topical route of administration PART 09: MARKET SEGMENTATION BY DRUG CLASS ? SSRIs ? PDE5 inhibitors ? Amide anesthetics ? Others PART 10: REGIONAL LANDSCAPE ? Regional comparison ? Premature ejaculation treatment market in Americas ? Premature ejaculation treatment market in EMEA ? Premature ejaculation treatment market in APAC ? Key leading countries ? Market opportunity PART 11: DECISION FRAMEWORK PART 12: DRIVERS AND CHALLENGES ? Market drivers ? Market challenges PART 13: MARKET TRENDS ? Growing online retail sales of drugs ? Increase in awareness of premature ejaculation ? New treatment methods PART 14: VENDOR LANDSCAPE ? Competitive scenario PART 15: KEY VENDOR ANALYSIS ? Absorption Pharmaceuticals ? Bayer ? Eli Lilly ? Regent Pacific Group ? Other prominent vendors PART 16: APPENDIX ? List of abbreviations List of Exhibits Exhibit 01: Global premature ejaculation treatment market: Overview Exhibit 02: Facts about premature ejaculation Exhibit 03: Severity levels of premature ejaculation Exhibit 04: Clinical diagnosis of premature ejaculation Exhibit 05: Premature ejaculation classification Exhibit 06: Global premature ejaculation treatment market 2016-2021 ($ millions) Exhibit 07: Five forces analysis Exhibit 08: Pipeline molecules by vendors Exhibit 09: Key clinical trials Exhibit 10: Global premature ejaculation treatment market by route of administration 2016 Exhibit 11: Global premature ejaculation treatment market by SSRIs 2016-2021 ($ millions) Exhibit 12: Global premature ejaculation treatment market by PDE5 inhibitors 2016-2021 ($ millions) Exhibit 13: Global premature ejaculation treatment market by amide anesthetics 2016-2021 ($ millions) Exhibit 14: Global premature ejaculation treatment market by others 2016-2021 ($ millions) Exhibit 15: Global premature ejaculation treatment market by region 2016-2021 (% share) Exhibit 16: Regional comparison Exhibit 17: Premature ejaculation treatment market in Americas 2016-2021 ($ millions) Exhibit 18: Premature ejaculation treatment market in Americas ? Year over year growth Exhibit 19: Premature ejaculation treatment market in EMEA 2016-2021 ($ millions) Exhibit 20: Premature ejaculation treatment market in EMEA ? Year over year growth Exhibit 21: Premature ejaculation treatment market in APAC 2016-2021 ($ millions) Exhibit 22: Premature ejaculation treatment market in APAC ? Year over year growth Exhibit 23: Key leading countries Exhibit 24: Pharmacologic efficacy of some SSRIs Exhibit 25: Premature ejaculation treatment drugs and their subsequent side effects Exhibit 26: Factors challenging the treatment of premature ejaculation Exhibit 27: Absorption Pharmaceuticals: Key highlights Exhibit 28: Absorption Pharmaceuticals: Strength assessment Exhibit 29: Absorption Pharmaceuticals: Strategy assessment Exhibit 30: Absorption Pharmaceuticals: Opportunity assessment Exhibit 31: Bayer: Key highlights Exhibit 32: Bayer: Strength assessment Exhibit 33: Bayer: Strategy assessment Exhibit 34: Bayer: Opportunity assessment Exhibit 35: Eli Lilly: Key highlights Exhibit 36: Eli Lilly: Strength assessment Exhibit 37: Eli Lilly: Strategy assessment Exhibit 38: Eli Lilly: Opportunity assessment Exhibit 39: Regent Pacific Group: Key highlights Exhibit 40: Regent Pacific Group: Strength assessment Exhibit 41: Regent Pacific Group: Strategy assessment Exhibit 42: Regent Pacific Group: Opportunity assessment
Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.
Primary research - Manufacturers/Suppliers, Channel partners, Industry experts, Strategic decision makers
Secondary research - Technavio internal repository, Industry journals and periodicals, Government bodies, Annual reports of key stakeholders
Data synthesis - Collation of data, Estimation of key figure, Analysis of derived insights
Data validation - Triangulation with data models, Reference against proprietary databases, Corroboration with industry experts
Qualitative analysis - Market drivers, Market challenges, Market trends, Five forces analysis
Quantitative analysis- Market size and forecast, Market segmentation, Geographical insights, Competitive landscape
Technavio’s database and industry-specific repositories are used for defining the hypothesis for the study, which is further fine-tuned through primary research involving industry experts. The success of our approach lies in the fact that we take the viewpoint of all stakeholders into consideration while analyzing an industry, and objectively assess each outlook.
Why Market Size Forecasters?